PATIENT CHARACTERISTICS AND HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH SEROTYPE 3 AND EMERGING SEROTYPE 15A PNEUMOCOCCAL DISEASE IN HONG KONG FROM 2007-2024
Author(s)
Jack Chi-him Lau, MPH1, Celine Sze-Ling Chui, PhD1, Cindy Thiow Koon Lim, PhD2, Kim Shijian Lao, PhD3, Grace Mengqin Ge, PhD3, See-Hwee Yeo, PhD4, Isaya Sukarom, PhD5.
1The University of Hong Kong, Hong Kong, China, 2IQVIA Solutions Asia, Singapore, Singapore, 3MSD Hong Kong, Hong Kong, China, 4MSD Singapore, Singapore, Singapore, 5MSD Thailand, Bangkok, Thailand.
1The University of Hong Kong, Hong Kong, China, 2IQVIA Solutions Asia, Singapore, Singapore, 3MSD Hong Kong, Hong Kong, China, 4MSD Singapore, Singapore, Singapore, 5MSD Thailand, Bangkok, Thailand.
OBJECTIVES: To describe patient characteristics and healthcare resource utilization (HCRU) associated with serotype (ST) 3 and ST15A pneumococcal disease (PD) in Hong Kong.
METHODS: This was a retrospective study which utilized electronic health records from the Hong Kong Clinical Data Analysis and Reporting System. Hospitalized ST3 and ST15A PD episodes between 2007-2024 were identified using the International Classification of Diseases, Ninth Revision Clinical Modification codes.
RESULTS: There were 206 ST3 and 20 ST15A PD hospitalization episodes identified. More than half (56.8%, n=117) of ST3 episodes were observed in males and 75.2% (n=155) involved adults. Among adult episodes, 60.6% (n=94) involved elderly aged ≥65 years. Pre-existing comorbidities were reported in 31.6% (n=65) of ST3 episodes, with chronic lung (10.2%, n=21) and chronic heart disease (8.3%, n=17) most frequently reported. Non-bacteremic pneumococcal pneumonia (NBPP) and bacteremic pneumonia accounted for 46.6% (n=96) and 44.2% (n=91) of ST3 episodes, respectively. The median length of hospitalization per visit among ST3 episodes was 17.0 days. Approximately 41.7% (n=86) of ST3 episodes involved admission to the intensive care unit (ICU), with a median ICU length of stay of 10.5 days. Among identified ST15A PD episodes, 60.0% (n=12) were observed in males and adults. 58.3% (n=7) of adult episodes involved elderly aged ≥65 years. Pre-existing comorbidities were reported in approximately 45.0% (n=9) of ST15A episodes. NBPP and bacteremic pneumonia accounted for 35.0% (n=7) and 25.0% (n=5) of ST15A episodes, respectively. The median length of hospitalization per visit among ST15A episodes was 16.0 days. Fewer than five ST15A episodes required admission to the ICU, with a median ICU length of stay of 4.5 days.
CONCLUSIONS: HCRU associated with ST3 and ST15A PD episodes remains substantial. As current vaccines administered in Hong Kong’s childhood immunization programme lack ST15A coverage, our findings support the need for strategies to address residual PD burden.
METHODS: This was a retrospective study which utilized electronic health records from the Hong Kong Clinical Data Analysis and Reporting System. Hospitalized ST3 and ST15A PD episodes between 2007-2024 were identified using the International Classification of Diseases, Ninth Revision Clinical Modification codes.
RESULTS: There were 206 ST3 and 20 ST15A PD hospitalization episodes identified. More than half (56.8%, n=117) of ST3 episodes were observed in males and 75.2% (n=155) involved adults. Among adult episodes, 60.6% (n=94) involved elderly aged ≥65 years. Pre-existing comorbidities were reported in 31.6% (n=65) of ST3 episodes, with chronic lung (10.2%, n=21) and chronic heart disease (8.3%, n=17) most frequently reported. Non-bacteremic pneumococcal pneumonia (NBPP) and bacteremic pneumonia accounted for 46.6% (n=96) and 44.2% (n=91) of ST3 episodes, respectively. The median length of hospitalization per visit among ST3 episodes was 17.0 days. Approximately 41.7% (n=86) of ST3 episodes involved admission to the intensive care unit (ICU), with a median ICU length of stay of 10.5 days. Among identified ST15A PD episodes, 60.0% (n=12) were observed in males and adults. 58.3% (n=7) of adult episodes involved elderly aged ≥65 years. Pre-existing comorbidities were reported in approximately 45.0% (n=9) of ST15A episodes. NBPP and bacteremic pneumonia accounted for 35.0% (n=7) and 25.0% (n=5) of ST15A episodes, respectively. The median length of hospitalization per visit among ST15A episodes was 16.0 days. Fewer than five ST15A episodes required admission to the ICU, with a median ICU length of stay of 4.5 days.
CONCLUSIONS: HCRU associated with ST3 and ST15A PD episodes remains substantial. As current vaccines administered in Hong Kong’s childhood immunization programme lack ST15A coverage, our findings support the need for strategies to address residual PD burden.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
EPH35
Topic
Epidemiology & Public Health
Disease
SDC: Infectious Disease (non-vaccine), STA: Vaccines